"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial of a blood test to monitor for early signs of melanoma coming back (DETECTION)
This trial aimed to measure small amounts of melanoma cancer cells that may be in the bloodstream after surgery.
Depending on the results some people would go on to have treatment with a drug called nivolumab.
The trial was for people who had early stage melanoma. This is stage 2B or 2C melanoma.
Cancer Research UK supported this trial.
More about this trial
Surgery is the usual treatment for melanoma that hasn’t spread. It gets rid of the cancer in most people. But sometimes it comes back or spreads elsewhere in the body. So researchers are looking for ways to treat people before this happens.
The trial team have developed a blood test to look for cancer cells in the blood even if a
We know from research that people who have ctDNA in their blood have a higher chance of the cancer coming back. You usually only have treatment if a scan shows that this has happened. Doctors think that having treatment earlier if you have ctDNA in your blood could help. But they aren’t sure so want to find out more.
In this trial you have regular ctDNA blood tests after surgery. You then have one of the following if the team find cancer cells in the blood:
- continue with regular ctDNA blood tests, routine scans and check ups
The main aims of the trial were to find out:
- how well the ctDNA blood test works to find cancer cells
- if ctDNA picks up that the melanoma is coming back earlier than scans
- if having nivolumab works for people who have ctDNA detected in their blood, prevents the cancer from coming back and improves how long they live
Summary of results
This trial closed earlier than planned. This was because of the recent changes to the standard treatment options for people with melanoma. No patients were
How to join a clinical trial
Professor Paul Lorigan
Cancer Research UK
The Christie NHS Foundation Trust
This is Cancer Research UK trial number CRUK/19/010.